Maxim Group set a $14.00 target price on Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Wednesday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the company. FBR & Co reissued a buy rating and set a $15.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 26th. Rodman & Renshaw reissued a buy rating and set a $17.00 price target on shares of Abeona Therapeutics in a research note on Sunday, August 21st. Cantor Fitzgerald initiated coverage on Abeona Therapeutics in a research note on Wednesday, September 7th. They set a buy rating and a $21.00 price target for the company. Finally, Zacks Investment Research raised Abeona Therapeutics from a sell rating to a hold rating in a research note on Monday, August 29th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Abeona Therapeutics has a consensus rating of Buy and a consensus price target of $14.50.
Abeona Therapeutics (NASDAQ:ABEO) traded down 5.3827% during midday trading on Wednesday, hitting $6.3299. The stock had a trading volume of 199,777 shares. Abeona Therapeutics has a 52-week low of $2.05 and a 52-week high of $7.00. The stock’s market cap is $212.34 million. The company’s 50 day moving average price is $5.08 and its 200-day moving average price is $3.35.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. Analysts forecast that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.
In other news, Director Todd Wider bought 5,000 shares of the firm’s stock in a transaction on Tuesday, September 20th. The stock was acquired at an average cost of $5.48 per share, with a total value of $27,400.00. Following the transaction, the director now directly owns 75,000 shares in the company, valued at approximately $411,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 13.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royce & Associates LP increased its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC increased its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares in the last quarter. Institutional investors and hedge funds own 19.95% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.